Kornimate/medical-research-clean huggingface dataset:
intraoperative ketamine and magnesium therapy for control of postoperative pain after a liposuction and lipoabdominoplasty

Conditions: Pain, Postoperative

Summary: lipoabdominoplasty and liposuction are one of the most common plastic surgeries. the management of postoperative pain is complex. non steroidal anti inflammatory drugs (nsaids) are insufficient, while opioids are avoided by their adverse effects and regional techniques are hampered by a premature discharge. in this context, the investigators seek an intraoperative multimodal analgesic technique blocking nmda receptors with ketamine plus magnesium to significantly decrease postoperative pain.


Eligibility criteria:
inclusion criteria: * female and male * 18 years or older * liposuction and lipoabdominoplasty * asa 1 and 2 * bmi 21-28 kg/m2 * full secondary education exclusion criteria: * patients with surgeries added to the main proceedings * scheduled to tuck in flor de lis or body lift * history of use of analgesic drugs 48 hours before surgery * peripheral central neurological diseases * known allergy will be excluded to medication in use in this study (ketamine, magnesium, clindamycin and penicillin or other)

Keywords: ketamine magnesium analgesia liposuction lipoabdominoplasty preemptive analgesia
the effect of kinesio taping on mobility, pain, balance and daily activities in total knee replacement patients

Conditions: Total Knee Anthroplasty

Summary: total knee arthroplasty (tka) is a surgical procedure performed to relieve pain and functional limitations caused by advanced gonarthrosis that cannot be managed with conservative methods. it is known that the postoperative rehabilitation program plays a crucial role in functionality and mobility in the postoperative period. pain and swelling are the most commonly reported minor complications that lead to functional limitations, often associated with decreased muscle strength. after tka, various current methods such as compression therapy and electrotherapy are employed to treat postoperative edema. typically, patients are discharged with a home exercise program once they are ambulatory. however, the return to daily living activities varies among patients, and some may experience prolonged recovery times. in our country and hospital, there is no standardized algorithm for postoperative care following tka. patients are often referred to rehabilitation clinics only when complications arise. due to issues with patient ambulation, there may be a need for inpatient care following tka. while traditional rehabilitation programs are used, alternative methods to facilitate early ambulation have emerged in recent years, one of which is kinesiology taping (kt). developed by kenso kase in the 1970s, kt is an elastic, wave-textured, waterproof, breathable cotton tape applied directly to the skin. when applied with various techniques, it helps alleviate pain, reduce edema, and provides mechanical support and joint protection. kt does not restrict movement; instead, its elastic structure opens the space between the dermis and fascia, aiding lymphatic and blood flow, thereby reducing swelling in the extremities. there are studies on the use of kt in postoperative patients beyond musculoskeletal pain conditions, particularly regarding its effectiveness in managing pain, swelling, and joint range of motion after shoulder and anterior cruciate ligament surgeries. although recent studies in the literature have explored the use of kt after tka, there is still no consensus on its efficacy and application methods. this study aims to investigate the potential effects or complications of kt treatment on balance, pain, mobility, and quality of life in patients undergoing rehabilitation after tka.


Eligibility criteria:
inclusion criteria: * patients aged 50-75 who have undergone total knee arthroplasty (tka) * patients able to mobilize independently * patients willing to participate in the treatment program * patients without any secondary conditions that could cause immobilization exclusion criteria: * patients who have undergone surgery due to cancer * renal insufficiency (gfr \&lt;30) * patients with local infection in the kinesiology taping application area * heart failure (stage iii-iv) * bmi \&gt;35 * cognitive impairment * copd (gold stage iii-iv)

Keywords: total knee arthroplasty kinesiotape pain edema
physical activity and fall prevention in geriatric inpatients in acute care: feasibility study

Conditions: Elderly

Summary: this study aims to evaluate the feasibility and the impact on physical performance and falls occurence among geriatric inpatients hospitalized in acute care unit.

having developed many tools to determine fall risk of 65 years and older patients, angers university hospital plans to develop a corrective action to prevent the occurrence of falls in this population. this study aims to assess the feasibility of a physical activity program with 3 difficulty levels (depending on the patient's risk of falling): easy (low fall risk), moderate (average fall risk) and difficult (high fall risk). the implementation process should be simply and fastly applicable in practice for routine care by paramedics.

Eligibility criteria:
inclusion criteria: * being 65 years old and older * being hospitalized in geriatric acute care unit of angers university hospital. * no contraindications to physical activity practice. * no contraindications to standing station and sitting station. * participants having given and signed an informed participation consent. if the participant is unable to answer, we will retain the disagreement expressed by a trusted person. * being affiliated to french social security exclusion criteria: * refusal of participation * persons aged under 65. * topics including hospitalization at the entrance should not exceed 3 days. * participation in concomitant clinical trial. * civil protection measures such as trusteeship, guardianship or backup justice underway.

Keywords: 65 years old or older hospitalized in geriatrics
food at home study

Conditions: Obesity; Diet, Healthy

Summary: the study objective is to develop an accessible home food environment assessment toolkit that includes valid and reliable paper and electronic tools targeting foods known to impact diet-related health that can be user-administered across literacy levels in english and spanish.


Eligibility criteria:
inclusion criteria: * speak spanish or english at home * 18 or older * primary grocery shopper or meal preparer exclusion criteria: * any person younger than 18 * lacks the capacity to consent * does not purchase the majority of the groceries for the home
instep plantar fasciotomy with and without gastrocnemius recession

Conditions: Plantar Fasciitis; Equinus Deformity

Summary: compare results of instep plantar fascial release with and without gastrocnemius recession

plantar fasciitis is one of the most common causes of heel pain. approximately 2 million americans seek treatment for plantar fasciitis every year, with 10% of the population developing plantar fasciitis over a lifetime. the vast majority of cases respond to conservative care; however, the 5-10% of cases that are recalcitrant to conservative measures may require surgical intervention. several surgical options do exist and are cited in the literature for treatment of recalcitrant plantar fasciitis. one such approach is the instep plantar fascial release, utilizing an approximately 2-3 cm plantar incision over the prominent fascial band, just distal to the fat pad of the heel. it has been demonstrated that many patients with plantar fasciitis also have an isolated contracture of the gastrocnemius, known as gastrocnemius equinus. gastrocnemius recession is performed to correct an isolated gastrocnemius contracture and recent studies have demonstrated its successful use in the treatment of recalcitrant foot pain. to date, no prospective studies exist examining the utilization of the gastrocnemius recession in combination with instep plantar fascial release in the treatment of recalcitrant plantar fasciitis. this prospective randomized trial will aim to compare the use of instep plantar fasciotomy both with and without gastrocnemius recession in the treatment of plantar fasciitis.

Eligibility criteria:
inclusion criteria: * patients that have failed conservative treatment for greater than 6 months. * patients with recalcitrant plantar fasciitis and simultaneous gastrocnemius contracture in the ipsilateral limb. contracture will be defined as the inability to dorsiflex the ankle past neutral with the knee in extension. exclusion criteria: * adjunctive procedure at the time of surgery. * history of heel spur surgery, plantar fasciotomy or extracorporeal shockwave therapy.

Keywords: instep plantar fasciotomy
effectiveness of laserpuncture and standard antiemetic on rinvr scores in adolescent patients undergoing chemotherapy

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: chemotherapy is a common treatment for treating cancer. chemotherapy induced nausea and vomiting (cinv) is nausea and vomiting that occurs after chemotherapy. complete protection of standard antiemetic drugs against cinv symptoms in children and adolescents receiving moderately and strongly emetogenic chemotherapy drugs was less than 50%. the side effects of chemotherapy in the form of cinv are so unpleasant that chemotherapy causes extreme anxiety and stress. the psychological characteristics of adolescents who have a greater perception of the changes that occur cause more frequent anxiety which can increase the risk of cinv. acupuncture with laserpuncture modality is a non-pharmacological therapy that has a good effect on cinv symptoms in adolescents. this research was conducted for the first time in brazil in 2019, while in indonesia there has never been any research on this matter. so it is hoped that this research will be the first research in indonesia to prove that the effect of laserpuncture plays a role in cinv symptoms in adolescents and can be an additional treatment in standard therapy for cinv problems in adolescents.

this is a clinical trial study to evaluate and compare the effects of laserpuncture and sham laserpuncture as a therapy for chemotherapy induced nausea and vomiting (cinv) . the subjects are 58 males/female and will be randomly assigned to 2 groups: (1) laserpunctur and (2) sham laserpuncture. the outcome will be assessed before treatment (baseline), in chemotherapy procedure and 3 days after chemotherapy. patients and the outcome assessors will be blinded to the group allocation.

Eligibility criteria:
inclusion criteria: 1. adolescent cancer patients aged 10 - 18 years 2. patients undergoing chemotherapy with moderate and/or strong emetogenic chemotherapy drugs 3. patients with cinv and/or at risk of cinv 4. willing to take part in research until completion 5. the patient has not received acupuncture therapy in the last 1 week exclusion criteria: 1. patients with cancerous lesions or ulcers at the location of the acupuncture points to be selected 2. patients with digestive tract organ malignancies with complaints of nausea and vomiting before chemotherapy 3. patients with unstable hemodynamic conditions
a superiority trial of the supera peripheral stent system in patients with femoro-popliteal artery disease

Conditions: Peripheral Arterial Disease

Summary: the purpose of this study (superiority trial) is to compare the supera® peripheral stent system with a standard nitinol self-expanding stent for treatment of femoro-popliteal arterial occlusive disease. hypothesis: the supera® stent is superior to a standard nitinol self-expanding stent, for treatment of femoro-popliteal artery disease in terms of (1) primary patency rate and (2) need for revascularization up to 24 months after stent insertion.


Eligibility criteria:
inclusion criteria: * patients with femoro-popliteal artery disease, who will require a stent femoro-popliteal following failed percutaneous transluminal angioplasty (pta) * target lesion length \<200mm * planned follow-up available for at least 24 months * written informed consent to participate in the study and agreement to comply with the study protocol must be obtained from the patient prior to initiation of any study-mandated procedure and randomization exclusion criteria: * life expectancy \<24 months * patients who cannot receive dual antiplatelet therapy (aspirin 100mg and clopidogrel 75mg) or anticoagulation therapy * patients with known allergies to: nitinol (nickel titanium); or contrast agent, that cannot be medically managed * participation in another study with investigational drug/device within the 30 days preceding and during the present study * previous enrolment into the current study * prior stenting at the location of intended stenting * patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system * enrolment of study investigator, his/her family members, employees and other dependent persons * if female and of childbearing potential: known pregnancy or a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating
a study to investigate the pharmacodynamic and pharmacokinetic interaction between aliskiren and furosemide in patients with heart failure

Conditions: Heart Failure

Summary: this study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.


Eligibility criteria:
inclusion criteria: * systolic or diastolic heart failure, diagnosed with either nyha functional class ii to iii at least 3 months prior to screening and on stable medication for at least 12 weeks. * patients must have met either of the criteria at screening: * documented left ventricular ejection fraction (lvef) greater than 20% but lower than 40% or * patients with a documented lvef greater than 40% and with a history of nt-pro-bnp\> 400pg/ml (or bnp \> 100pg/ml) within 12 months of screening. exclusion criteria: * treatment with angiotensin receptor blockers (arbs), aldosterone receptor antagonists and diuretics (other than furosemide) within 3 weeks of first dose and during the study. beta blockers were permitted provided the dose was stable for at least 3 weeks before the first dose and remains so throughout the study. * hypertrophic cardiomyopathy (hcmp). * if a subject is currently treated with furosemide, the dose must be stable for at least 3 weeks before the first dose and the dose must not exceed 60 mg daily * stable heart failure requiring treatment with both an ace inhibitor and an arb or current acute decompensated heart failure. * mean sitting systolic blood pressure ≥160 mmhg and/or mean sitting diastolic blood pressure ≥ 100mmhg and/or secondary forms of hypertension. * persistent sitting systolic blood pressure \<90 mmhg. * history of angioedema. other protocol-defined inclusion/exclusion criteria may apply

Keywords: heart failure, aliskiren, furosemide, diuretic efficacy, interaction
effect of intermittent infusion versus continuous infusion of vancomycin on kidney failure in critically ill patients

Conditions: Gram-Positive Bacterial Infections; Nephrotoxicity; Sepsis

Summary: this is a randomized, controlled multicenter clinical trial. the purpose of this study is to compare the continuous infusion of vancomycin with intermittent infusion regarding the effectiveness to reach the target serum level and the relationship between infusion type and nephrotoxicity in critically ill patients.

the vancomycin is a glycopeptide antimicrobial which has been used for 50 years against gram-positive microorganisms and remains effective against multiresistant bacteria as the methicillin resistant staphylococcus aureus (mrsa), the main microorganism causing nosocomial infections. around the world, the continuous infusion of vancomycin has been studied and associated with less rate of nephrotoxicity. this is a randomized, controlled multicenter clinical trial that will compare continuous infusion with the intermittent vancomycin infusion, the relationship between infusion type with rate of nephrotoxicity and the time to target therapeutic serum in critically ill patients at the intensive care units of the cancer institute of the state of sao paulo (icesp) and the heart institute (incor).

Eligibility criteria:
inclusion criteria: * critically ill patients * treatment with vancomycin * preserved renal function. exclusion criteria: * cystic fibrosis * chronic renal failure * acute renal failure * having received vancomycin in the last 24 hours * vancomycin hypersensibility

Keywords: vancomycin infusion critical ill patients mrsa
dorsal genital nerve stimulation for bladder management after sci

Conditions: Spinal Cord Injuries; Neurogenic Bladder; Neurogenic Detrusor Overactivity; Neurogenic Bladder Dysfunction

Summary: following spinal cord injury signals between the brain and the bladder are disrupted. as a result the bladder often becomes overactive which can lead to the need for frequent trips to the toilet, regular incontinence episodes and a decreased quality-of-life. neuromodulation is a therapy that aims to target the nerves that become overactive controlling the bladder, stopping the bladder overactivity on demand using an external (non-invasive) nerve stimulation box and sticker electrodes placed on the penis or clitoris. this study is a pilot study that aims to investigate neuromodulation for improving symptoms of bladder overactivity when used by 10 people over eight weeks at home. we will assess whether using the device improves bladder capacity, incontinence, frequency of needing the toilet and whether there are any longer lasting changes after 8 weeks. finally, the study will aim to find out the acceptability of using this type of therapy for participants and the acceptability of the device we are using. participants in this trial will participate over 13 weeks and need to visit our centre in stanmore to have urodynamics tests in the 1st, 9th and 13th week. at home they will use a small stimulation device on a daily basis for 8 weeks to control overactivity in the bladder. whilst at home they will record relevant outcomes in several three-day diaries and questionnaires. they will record baseline data before starting stimulation and for 4 weeks after.


Eligibility criteria:
inclusion criteria: * spinal cord injury (suprasacral, ais a-d); * \>18 years old, no upper age limit; * sci sustained \>6 months ago; * ndo; * capable of using the device at home either independently or with existing support. * male or female * willing and able to provide informed consent exclusion criteria: * recipient of intra-detrusor botulinum toxin injections within the last 6 months; * previous surgical intervention on bladder sphincters; * pregnancy; * cardiac pacemaker; * active sepsis; * history of significant autonomic dysreflexia; * poorly controlled epilepsy; * patients with a cancerous tumour in the area of electrical stimulation
si joint fusion and decortication using the simmetry system

Conditions: Sacroiliac Joint Dysfunction

Summary: the purpose of the si joint fusion and decortication using the simmetry system study is to evaluate the simmetry sacroiliac joint fusion system for fusion of the si joint and relief of si joint pain symptoms.

this is a prospective, non-randomized post market study designed to collect data on si joint fusion and subject back pain following implant of the simmetry device. the study will be conducted at a single site and 25 subjects will be implanted and followed through 24 months. data will be collected pre-operatively, implant, and at specified follow-up time points through 24 months.

Eligibility criteria:
inclusion criteria: * subjects must be indicated for the simmetry device according to the approved simmetry labeling * subject has two (2) positive (experiences pain) provocative tests for sij pain; for example, compression, thigh thrust, faber, distraction or gaenslen's * subject has documentation of failed, non-operative management of sij pain for ≥ 6 months prior to surgery; for example, use of medications, braces, si belts, orthotics, physical therapy or manual manipulation * the subject has two (2) diagnostic sij injection at least one (1) resulting in a ≥50% decrease in pain in the joint(s) from the anesthetic portion of the injection * the subject has vas back pain score of ≥ 50 mm * the subject is at least 18 years of age and skeletally mature * the subject agrees and is able to comply with study requirements exclusion criteria: * subjects contraindicated per the cleared labeling will be excluded from participation in the study * the subject has pelvic soft tissue or bony tumors * the subject has had any trauma causing fracture of the sacrum or iliac bones or has had spinal trauma leading to a neurological deficit * the subject has a history of a central nervous system (cns) disorder(s) * the subject is indicated for or awaiting other spine surgery * the subject is pregnant or is planning on becoming pregnant in the next two years * the subject has uncontrolled insulin dependent diabetes mellitus (type 1 diabetes) * the subject has chemical dependency abuse problems as evidenced by a history of abusing drugs which is documented in their past medical history or is elicited from an interview * the subject is receiving or seeking worker's compensation, disability remuneration, and/or involved in litigation related to low back or sij pain * the subject has a history of significant emotional or psychosocial disturbance (untreated or uncontrolled anxiety attacks, obsessive/compulsive disorders, depression or schizophrenia) as documented in their past medical history or elicited by an interview

Keywords: sacroiliac joint fusion sij fusion si joint sij